The short version of obesity research fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-12 and is reviewed periodically as new material appears.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Many Liliaceae are important ornamental plants, grown for their attractive flowers and involved in a major floriculture of cut flowers and dry bulbs. Some species are poisonous if eaten and can have adverse health effects in humans and household pets. Some species have been used as famine food. Lilies and tulips have symbolic and decorative value, appearing frequently in paintings and the decorative arts.
downregulation Also repression or suppression. Any process, natural or artificial, which decreases the level of gene expression of a certain gene. A gene which is observed to be expressed at relatively low levels (such as by detecting lower levels of its mRNA transcripts) in one sample compared to another sample is said to be downregulated. Contrast upregulation.
Respiratory depression when appropriate equipment is not available. Although it has previously been thought that morphine was contraindicated in acute pancreatitis, a review of the literature shows no evidence for this.
=== Reduced Bleeding === In vivo haemostasis efficacy studies were conducted using rat models of liver puncture and femoral artery injury. For both models, K37 and K81 (10 mg) were applied to cover the wound areas. In the liver puncture model, bleeding time significantly decreased with recombinant K37 (approximately 38 s) and K81 (approximately 40 s) compared to the vehicle alone (approximately 170 s, p < .01), with notably reduced total blood loss (p < .01). Furthermore, in the femoral artery injury model, the recombinant keratin proteins significantly reduced bleeding time compared to the control group (approximately 50 s vs. 270 s). Notably, K37 and K81 exhibited stronger haemostatic effects than extracted keratins (approximately 80 s) in treating rat liver injury. Additionally, the recombinant keratin proteins demonstrated a robust capacity to promote the formation of a fibrin clot at the injury site, effectively stopping the bleeding. Consequently, recombinant human hair keratins offer potential for developing novel haemostatic products based on keratin biomaterials.
The Chief Minister of the state of Maharashtra - the state with the biggest GDP in India and home to its financial capital Mumbai - has also welcomed the retail reform., Tarun Gogoi, the Chief Minister of Assam, an eastern state in India, announcing his support to the retail reform, claimed "this will go a long way in bringing about a change in rural economy. The decision will boost agriculture and allied sectors, manufacturing, logistics, integrated cold chains, refrigerated transportation and food processing facilities in a big way." Criticising the BJP-organised opposition, Gogoi claimed that these parties who had just a few years ago dubbed opening up retail as good for India, are now singing a different tune.
Sources: en.wikipedia.org
A year later, a further discovery was made at Lindow Moss, just 250 m (820 ft) southwest of the Lindow Woman. On 1 August 1984, Andy Mould, who had been involved in the discovery of Lindow Woman, took what he thought was a piece of wood off the elevator of the peat-shredding machine. He threw the object at Eddie Slack, his workmate. When it hit the ground, peat fell off the object and revealed it to be a human foot. The police were called, and the foot was taken away for examination. At the same time Rachel Pugh, a trainee journalist for The Wilmslow World, was tipped off about the discovery. At the urging of her editor, she cycled out to the site of the discovery and persuaded the two men to show her where the foot had been excavated. Recognising the possible historical significance of the find, she told the diggers to stop work at once, and alerted Rick Turner, the Cheshire County Archaeologist, who subsequently succeeded in finding the rest of the body, which later became known as Lindow Man. Some skin had been exposed and had started to decay, so to prevent further deterioration of the body, it was re-covered with peat. The complete excavation of the block containing the remains was performed on 6 August. Until it could be dated, it was moved to the Macclesfield District General Hospital for storage. As the body of Malika Reyn-Bardt had still not been found, it was initially thought possible the body might be hers, until it was determined to be male, and radiocarbon dated.
His only other appearance came in Game 6, when he pitched a scoreless fourth and fifth inning's in Pittsburgh's 12–0 defeat. Despite posting a 15.43 ERA, Mizell became a World Series champion for the only time in his career, as the Pirates clinched the series in Game 7 on Bill Mazeroski's game-ending home run. Entering the 1961 season, Sports Illustrated predicted that Mizell "may win more this year." Indeed, he got off to a 4–1 start, posting a 3.57 ERA through May 24. However, Mizell slumped in 1961. He lost seven straight decisions through the end of July, getting moved to the bullpen and only making two starts between June 15 and July 27. Used as a starter during the week of August 6–12, however, he won two games, the second of which was a five-hit shutout of the Phillies. It would be his only shutout of the year. Mizell started two more games that month but lost both and was used only twice in September, as a relief pitcher. In 25 games (17 starts), he had a 7–10 record, a 5.04 ERA, 37 strikeouts, and 31 walks in 100 innings pitched. Mizell was slightly late for spring training due to the birth of his second son in 1962. In his first start of the year, he defeated the expansion New York Mets, limiting them to one unearned run over seven innings. That was his only win through May 7, as he posted a 4.96 ERA in three games (three starts). On May 7, he was traded to the Mets for Jim Marshall, much to the chagrin of Pirates fans and players, with whom Mizell had been popular.
==== Emotional health ==== Researcher Dianne Hales described an emotionally healthy person as someone who exhibits flexibility and adaptability to different circumstances, a sense of meaning and affirmation in life, an "understanding that the self is not the center of the universe", compassion and the ability to be unselfish, an increased depth and satisfaction in intimate relationships, and a sense of control over the mind and body.
This inhibition can lead to a depletion of dopamine and norepinepherine in the brain due to the lack of the precursor L-DOPA (L-3,4-dyhydroxyphenylalanine) which is synthesized by tyrosine hydroxylase. This drug is rarely used and can cause depression, but it is useful in treating pheochromocytoma and also resistant hypertension. Older examples of inhibitors mentioned in the literature include oudenone and aquayamycin.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.